Your browser doesn't support javascript.
loading
The evidence base of US Food and Drug Administration approvals of novel cancer therapies from 2000 to 2020.
Gloy, Viktoria; Schmitt, Andreas M; Düblin, Pascal; Hirt, Julian; Axfors, Cathrin; Kuk, Hanna; Pereira, Tiago V; Locher, Clara; Caquelin, Laura; Walter-Claudi, Martin; Lythgoe, Mark P; Herbrand, Amanda; Kasenda, Benjamin; Hemkens, Lars G.
Afiliación
  • Gloy V; Department of Clinical Research, University of Basel and University Hospital Basel, Basel, Switzerland.
  • Schmitt AM; Department of Clinical Research, University of Basel and University Hospital Basel, Basel, Switzerland.
  • Düblin P; Department of Medical Oncology, University Hospital Basel, Basel, Switzerland.
  • Hirt J; Department of Medical Oncology, The Royal Marsden Hospital NHS Foundation Trust, London, UK.
  • Axfors C; Department of Clinical Research, University of Basel and University Hospital Basel, Basel, Switzerland.
  • Kuk H; Department of Clinical Research, University of Basel and University Hospital Basel, Basel, Switzerland.
  • Pereira TV; International Graduate Academy, Institute of Health and Nursing Science, Medical Faculty, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.
  • Locher C; Institute of Nursing Science, Department of Health, Eastern Switzerland University of Applied Sciences, St. Gallen, Switzerland.
  • Caquelin L; Department for Women's and Children's Health, Uppsala University, Uppsala, Sweden.
  • Walter-Claudi M; Meta-Research Innovation Center at Stanford (METRICS), Stanford University, Stanford, California, USA.
  • Lythgoe MP; Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
  • Herbrand A; Applied Health Research Centre (AHRC) Li Ka Shing Knowledge Institute of St. Michael's Hospital University of Toronto Canada.
  • Kasenda B; Department of Health Sciences, University of Leicester, Leicester, UK.
  • Hemkens LG; Univ Rennes, CHU Rennes, Inserm, Centre d'investigation clinique de Rennes (CIC1414), service de pharmacologie clinique, Institut de recherche en santé, environnement et travail (Irset), Rennes, France.
Int J Cancer ; 152(12): 2474-2484, 2023 06 15.
Article en En | MEDLINE | ID: mdl-36779785
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 Problema de salud: 1_medicamentos_vacinas_tecnologias Asunto principal: Neoplasias / Antineoplásicos Tipo de estudio: Clinical_trials Aspecto: Patient_preference Límite: Humans País/Región como asunto: America do norte Idioma: En Revista: Int J Cancer Año: 2023 Tipo del documento: Article País de afiliación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 Problema de salud: 1_medicamentos_vacinas_tecnologias Asunto principal: Neoplasias / Antineoplásicos Tipo de estudio: Clinical_trials Aspecto: Patient_preference Límite: Humans País/Región como asunto: America do norte Idioma: En Revista: Int J Cancer Año: 2023 Tipo del documento: Article País de afiliación: Suiza